Regeneron Pharmaceuticals, Inc.
American biotechnology company headquartered in Tarrytown, New York; originally focused on neurotrophic factors, has expanded into cytokine and tyrosine kinase receptor research, developing treatments for eye diseases, cancer, and infectious diseases.
Clinical Trials
794
385 active
Approvals
13
Total approvals
Agencies
1
Regulatory bodies
Founded
1988
Active, not recruiting
366
46.1%
Available
7
0.9%
Completed
233
29.4%
Enrolling By Invitation
1
0.1%
No Longer Available
3
0.4%
Not yet recruiting
18
2.3%
Recruiting
94
11.8%
Temporarily Not Available
1
0.1%
Terminated
48
6.0%
Unknown
7
0.9%
Withdrawn
16
2.0%
- GSK has secured full global rights to Chimagen Biosciences' unnamed trispecific T-cell engager for multiple myeloma in a deal worth up to $750 million. - The preclinical asset is designed to bind T cells while targeting two tumor-associated antigens, aiming for deeper responses and better tolerability than existing engagers. - GSK plans to begin Phase 1 testing in 2027, adding to a myeloma portfolio anchored by the BCMA-directed antibody-drug conjugate Blenrep. - The deal is GSK's second with Chimagen, following the 2024 licensing of the CD19/CD20-targeted T-cell engager CMG1A46 for B-cell malignancies and autoimmune disease.
- Parabolus Medicines' lead candidate zolocatetide, an alpha-helical peptide drug, achieved a 74% objective response rate across 38 desmoid tumor patients who had typically progressed on prior therapy. - The drug targets the beta-catenin/TCF transcription factor complex, implicated in roughly 10% of all cancers and long considered undruggable by small molecules and biologics. - Parabolus raised $770 million in the largest venture-backed biotech IPO on record in 2026, with a Phase 3 desmoid tumor trial planned for H1 2027. - The company's platform uses over 3,000 unnatural amino acids and hundreds of stabilization chemistries to reach flat, pocket-free intracellular protein surfaces.
- The FDA accepted Intellia Therapeutics' Biologics License Application for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema and granted Priority Review with a PDUFA date of March 10, 2027. - The application is supported by global Phase 3 HAELO data showing an 87% reduction in mean monthly attacks versus placebo over the six-month efficacy evaluation period. - The FDA has indicated it does not currently plan to convene an advisory committee, and Intellia aims to launch lonvo-z commercially in the first half of 2027 if approved. - If cleared, lonvo-z would become the world's first in vivo CRISPR-based therapy and the only one-time treatment for HAE, potentially shifting care away from lifelong prophylactic regimens.
- The ANGPTL3 inhibitors market was valued at USD 0.21 billion in 2025 and is projected to reach USD 3.48 billion by 2035, at a 32.4% CAGR. - Monoclonal antibodies led the market with 71% share in 2025, driven by Regeneron's EVKEEZA, the sole FDA-approved ANGPTL3 inhibitor for homozygous familial hypercholesterolemia. - Arrowhead's zodasiran is advancing into Phase III development following positive Phase IIb ARCHES-2 results, positioning RNAi therapeutics as the fastest-growing drug class. - Verve Therapeutics' VERV-201, an in vivo base-editing therapy, is advancing toward potentially one-time, permanent ANGPTL3 reduction for refractory hypercholesterolemia and HoFH.
- A Nature correspondence argues that pre-clinical data interpretation must be grounded in clinical context to avoid misleading translational conclusions. - The exchange involves researchers from The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, and The University of Chicago. - The reply clarifies that the Matters Arising discussion concerns the broader clinical implications of findings rather than mechanistic aspects. - Authors disclose extensive industry relationships, including consulting, funding, and patent interests relevant to radiation oncology and cancer research.
- The novel hypercholesterolemia drugs market is projected to grow from USD 17.6 billion in 2026 to USD 42.8 billion by 2036, a 9.3% CAGR. - PCSK9 inhibitors are forecast to hold a 42.0% drug-class share in 2026, spanning monoclonal antibodies, inclisiran-based siRNA, and the new oral enlicitide. - Merck's Lipfendra (enlicitide) gained FDA approval in July 2026 as the first once-daily oral PCSK9 inhibitor for adults with hypercholesterolemia. - Injectable therapies lead with a 57.0% route-of-administration share, while gene-editing programs from Verve, CRISPR Therapeutics, and Eli Lilly advance toward one-time treatment.
- Scientists sequenced over one million genomes across three continents and identified rare FNIP1 loss-of-function variants linked to a 60% lower risk of cardiometabolic diseases. - Carriers of the mutation—roughly one in 7,000 people—show lower blood lipids, less liver fat, lower blood sugar, and proportionally more muscle. - The FNIP1 gene normally slows cellular calorie-burning machinery; disabling it causes the body to burn energy faster and use fat instead of storing it. - Researchers at Regeneron Pharmaceuticals suggest the findings could lead to drugs that mimic the mutation's protective metabolic effects.
- Samchundang Pharm has reached a settlement with Regeneron Pharmaceuticals and Bayer Consumer Care to conclude the global patent dispute over SCD411, its Eylea (aflibercept 2 mg) biosimilar. - The agreement dismisses all pending patent litigation in Europe, Japan, and South Korea, following earlier settlements covering the United States and Canada. - The resolution substantially clears legal uncertainties that had been blocking commercialization, shifting the key variable for SCD411's value from regulatory approval to actual sales performance. - Samchundang Pharm plans to accelerate overseas expansion of its ophthalmic biosimilars, supplying SCD411 under the Vizempre brand in Canada, Europe, and South Korea.
- Two new industry reports from ResearchAndMarkets.com provide comprehensive analysis of over 1,859 clinical-stage partnering agreements and 1,567 royalty-disclosing licensing transactions in the pharmaceutical and biotechnology sectors. - The clinical-stage report covers deal structures, upfront payments, milestone triggers, and royalty rates across Phase I, II, and III agreements, with contract documents where available. - The royalty rates report examines financial terms across 1,567 licensing transactions since 2015, offering benchmarking data on royalty clauses, license fees, and payment structures. - Both resources are designed to help biopharma dealmakers benchmark deal structures, optimize negotiation strategies, and assess partner flexibility in clinical-stage and royalty-based collaborations.
- Attovia Therapeutics priced an upsized IPO of 17 million shares at $17.00 per share, raising $289.0 million in gross proceeds on August 4, 2026. - The clinical-stage immunology company's lead asset ATTO-1310, an IL-31-targeting fusion protein, completed Phase I dosing in Q1 2026 with data showing favorable tolerability and rapid, deep itch relief. - Proceeds will fund clinical development of ATTO-1310 and the bispecific ATTO-2306 targeting IL-13 and IL-31, with remainder allocated to the trispecific ATTO-1091 for inflammatory bowel disease. - The company had raised $255.8 million in private capital since its 2023 founding, backed by Deep Track Capital, Frazier Life Sciences, Goldman Sachs Alternatives, and venBio.
